Clinical Trial Update: A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC) [Phase 1]

View source ↗

Summary

Phase 1b study of volociximab in combination with carboplatin, paclitaxel, and bevacizumab for first-line advanced non-small cell lung cancer; the trial status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• Volociximab (volociximab)

Snippet

Sponsor: Abbott | Conditions: Non-small Cell Lung Cancer | Phase 1 | Status: COMPLETED